Physicochemical Properties
| Molecular Formula | C3H6O4 |
| Molecular Weight | 106.08 |
| Exact Mass | 106.027 |
| CAS # | 28305-26-2 |
| Related CAS # | L-Glyceric acid sodium;146298-95-5 |
| PubChem CID | 6326776 |
| Appearance | Typically exists as solid at room temperature |
| LogP | -1.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 7 |
| Complexity | 69.3 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | OC[C@@H](C(=O)O)O |
| InChi Key | RBNPOMFGQQGHHO-REOHCLBHSA-N |
| InChi Code | InChI=1S/C3H6O4/c4-1-2(5)3(6)7/h2,4-5H,1H2,(H,6,7)/t2-/m0/s1 |
| Chemical Name | (2S)-2,3-dihydroxypropanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Human Endogenous Metabolite |
| ln Vitro | Another name for primary hyperoxaluria type 2 (PH2) is L-glyceric aciduria. L-glyceric acid is excreted as a result of the metabolic abnormality, which is caused by deficits in D-glycerate dehydrogenase and glyoxylate reductase. This is the primary diagnostic marker for PH2[1][2]. |
| References |
[1]. Chiral liquid chromatography tandem mass spectrometry in the determination of the configuration of glyceric acid in urine of patients with D-glyceric and L-glyceric acidurias. Biomed Chromatogr. 2002 May;16(3):191-8. [2]. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003 Oct;18(10):986-91. |
| Additional Infomation |
L-glyceric acid is an optically active form of glyceric acid having L-configuration. It is a glyceric acid and a (2S)-2-hydroxy monocarboxylic acid. It is an enantiomer of a D-glyceric acid. (2S)-2,3-dihydroxypropanoic acid has been reported in Lotus burttii, Lotus tenuis, and other organisms with data available. |
Solubility Data
| Solubility (In Vitro) | DMSO: 250 mg/mL (2356.71 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (19.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (19.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (19.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.4268 mL | 47.1342 mL | 94.2685 mL | |
| 5 mM | 1.8854 mL | 9.4268 mL | 18.8537 mL | |
| 10 mM | 0.9427 mL | 4.7134 mL | 9.4268 mL |